BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 26642214)

  • 1. Outcomes in a Cohort of Patients Started on Antiretroviral Treatment and Followed up for a Decade in an Urban Clinic in Uganda.
    Castelnuovo B; Kiragga A; Musaazi J; Sempa J; Mubiru F; Wanyama J; Wandera B; Kamya MR; Kambugu A
    PLoS One; 2015; 10(12):e0142722. PubMed ID: 26642214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of treatment outcomes for patients on first-line regimens in US President's Emergency Plan for AIDS Relief (PEPFAR) clinics in Uganda: predictors of virological and immunological response from RV288 analyses.
    Crawford KW; Wakabi S; Magala F; Kibuuka H; Liu M; Hamm TE
    HIV Med; 2015 Feb; 16(2):95-104. PubMed ID: 25124078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring and switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: collaborative analysis.
    Haas AD; Keiser O; Balestre E; Brown S; Bissagnene E; Chimbetete C; Dabis F; Davies MA; Hoffmann CJ; Oyaro P; Parkes-Ratanshi R; Reynolds SJ; Sikazwe I; Wools-Kaloustian K; Zannou DM; Wandeler G; Egger M;
    Lancet HIV; 2015 Jul; 2(7):e271-8. PubMed ID: 26423252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-line antiretroviral therapy durability in a 10-year cohort of naïve adults started on treatment in Uganda.
    Castelnuovo B; Kiragga A; Mubiru F; Kambugu A; Kamya M; Reynolds SJ
    J Int AIDS Soc; 2016; 19(1):20773. PubMed ID: 27319742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in Southern African adults.
    Nachega JB; Hislop M; Dowdy DW; Gallant JE; Chaisson RE; Regensberg L; Maartens G
    AIDS; 2008 Oct; 22(16):2117-25. PubMed ID: 18832875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High rates of viral suppression in adults and children with high CD4+ counts using a streamlined ART delivery model in the SEARCH trial in rural Uganda and Kenya.
    Kwarisiima D; Kamya MR; Owaraganise A; Mwangwa F; Byonanebye DM; Ayieko J; Plenty A; Black D; Clark TD; Nzarubara B; Snyman K; Brown L; Bukusi E; Cohen CR; Geng EH; Charlebois ED; Ruel TD; Petersen ML; Havlir D; Jain V
    J Int AIDS Soc; 2017 Jul; 20(Suppl 4):21673. PubMed ID: 28770596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term immune and virological response in HIV-infected patients receiving antiretroviral therapy.
    Silveira MP; Silveira CP; Guttier MC; Page K; Moreira LB
    J Clin Pharm Ther; 2016 Dec; 41(6):689-694. PubMed ID: 27676134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiretroviral treatment Long-Term (ALT) cohort: a prospective cohort of 10 years of ART-experienced patients in Uganda.
    Castelnuovo B; Mubiru F; Kiragga AN; Musomba R; Mbabazi O; Gonza P; Kambugu A; Ratanshi RP
    BMJ Open; 2018 Feb; 8(2):e015490. PubMed ID: 29467129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Outcomes on Antiretroviral Therapy in a Large Scale-Up Program in Nigeria.
    Meloni ST; Chang CA; Eisen G; Jolayemi T; Banigbe B; Okonkwo PI; Kanki PJ
    PLoS One; 2016; 11(10):e0164030. PubMed ID: 27764094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-term and long-term clinical and immunological consequences of stopping antiretroviral therapy in HIV-infected patients with preserved immune function.
    Imaz A; Olmo M; Peñaranda M; Gutiérrez F; Romeu J; Larrousse M; Domingo P; Oteo JA; Curto J; Vilallonga C; Masiá M; López-Aldeguer J; Iribarren JA; Podzamczer D;
    Antivir Ther; 2013; 18(1):125-30. PubMed ID: 22805174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort.
    Paris D; Ledergerber B; Weber R; Jost J; Flepp M; Opravil M; Ruef C; Zimmerli S
    AIDS Res Hum Retroviruses; 1999 Dec; 15(18):1631-8. PubMed ID: 10606086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two-year outcomes of children on non-nucleoside reverse transcriptase inhibitor and protease inhibitor regimens in a South African pediatric antiretroviral program.
    Jaspan HB; Berrisford AE; Boulle AM
    Pediatr Infect Dis J; 2008 Nov; 27(11):993-8. PubMed ID: 18818556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triple nucleoside reverse transcriptase inhibitor- vs. nonnucleoside reverse transcriptase inhibitor-containing regimens as first-line therapy: efficacy and durability in a prospective cohort of French HIV-infected patients.
    Cuzin L; Pugliese P; Bugnon F; Delpierre C; Cua E; Billaud E; Massip P; Raffi F; Dellamonica P
    HIV Med; 2005 Nov; 6(6):388-95. PubMed ID: 16268820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Descriptive analysis of World Health Organization-recommended second-line antiretroviral treatment: A retrospective cohort data analysis.
    Gumede SB; Fischer A; Venter WDF; Lalla-Edward ST
    S Afr Med J; 2019 Nov; 109(12):919-926. PubMed ID: 31865953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Performance of a World Health Organization first-line regimen (stavudine/lamivudine/nevirapine) in antiretroviral-naïve individuals in a Western setting.
    Tam LW; Hogg RS; Yip B; Montaner JS; Harrigan PR; Brumme CJ
    HIV Med; 2007 Jul; 8(5):267-70. PubMed ID: 17561871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reasons for first line ART modification over the years during the ART scale up in Uganda.
    Castelnuovo B; Mubiru F; Kalule I; Kiragga A
    AIDS Res Ther; 2019 Oct; 16(1):31. PubMed ID: 31597561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adherence, virological and immunological outcomes for HIV-infected veterans starting combination antiretroviral therapies.
    Braithwaite RS; Kozal MJ; Chang CC; Roberts MS; Fultz SL; Goetz MB; Gibert C; Rodriguez-Barradas M; Mole L; Justice AC
    AIDS; 2007 Jul; 21(12):1579-89. PubMed ID: 17630553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term HIV treatment outcomes and associated factors in sub-Saharan Africa: multicountry longitudinal cohort analysis.
    Inzaule SC; Kroeze S; Kityo CM; Siwale M; Akanmu S; Wellington M; de Jager M; Ive P; Mandaliya K; Stevens W; Steegen K; Nankya I; Boender TS; Ondoa P; Sigaloff KCE; de Wit TFR; Hamers RL
    AIDS; 2022 Aug; 36(10):1437-1447. PubMed ID: 35608116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low Incidence of HIV-1C Acquired Drug Resistance 10 Years after Roll-Out of Antiretroviral Therapy in Ethiopia: A Prospective Cohort Study.
    Mulu A; Maier M; Liebert UG
    PLoS One; 2015; 10(10):e0141318. PubMed ID: 26512902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of the Botswana national HIV/AIDS treatment programme from 2002 to 2010: a longitudinal analysis.
    Farahani M; Vable A; Lebelonyane R; Seipone K; Anderson M; Avalos A; Chadborn T; Tilahun H; Roumis D; Moeti T; Musuka G; Busang L; Gaolathe T; Malefho KC; Marlink R
    Lancet Glob Health; 2014 Jan; 2(1):e44-50. PubMed ID: 25104635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.